Dinical value of blood biomarker ST2 in patients with chronic heart failure

Cover Page

Cite item

Full Text

Abstract

Stimulating growth factor expressed by gene 2 (ST2) and natriuretic peptides (BNP and NT-proBNP) reflect the flow of two different, but intersecting biological processes, so the markers provide independent and complementary information on the patient's condition. Being markers of hemodynamic instability or stretching of cardiomyocytes NT-proBNP/BNP is more suitable for detecting chronic heart failure, but this is not enough to rehospitalize patients for 30 days with the predictive qualities of this marker. ST2 is the strongest and clinically significant prognostic marker of cumulative cardiovascular events and mortality. The use of new highly specific cardiobiomarkers will make it possible to predict the development of cardiovascular complications with a high degree of predictive value, and therefore will allow prophylactically prescribing appropriate pathogenetic therapy aimed at improving the quality of life of patients, reducing mortality from cardiovascular diseases and reducing the economic costs of the state for treating heart failure and cardiovascular complications.

About the authors

Amina M. Alieva

Pirogov Russian National Research Medical University

Email: amisha_alieva@mail.ru
канд. мед. наук, доц. каф. Moscow, Russia

Tatiana V. Pinchuk

Pirogov Russian National Research Medical University

Email: doktor2000@inbox.ru
канд. мед. наук, доц. Moscow, Russia

Ilda I. Almazova

National Research Center for Therapy and Preventive Medicine

врач-преподаватель Moscow, Russia

Olga A. Ettinger

Pirogov Russian National Research Medical University

канд. мед. наук, доц. каф. Moscow, Russia

Ramiz K. Valiev

Loginov Moscow Clinical Scientific and Practical Center

канд. мед. наук, зав. Moscow, Russia

Maxim A. Batov

Pirogov Russian National Research Medical University

студент Moscow, Russia

Igor G. Nikitin

Pirogov Russian National Research Medical University

д-р мед. наук, проф., зав. каф. Moscow, Russia

References

  1. Pascual-Figal DA, Lax A, Perez-Martinez MT, et al. Clinical relevance of sST2 in cardiac diseases. Clin Chem Lab Med. 2016;54(1):29-35. doi: 10.1515/cclm-2015-0074
  2. Januzzi JL Jr, Ahmad T, Mulder H, et al. Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2019;74(9):1205-17. doi: 10.1016/j.jacc.2019.06.055
  3. Ciccone MM, Cortese F, Gesualdo M, et al. A Novel Cardiac Bio-Marker: ST2: A Review. Molecules. 2013;18(12):15314-28. doi: 10.3390/molecules181215314
  4. Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117:1538-49. doi: 10.1172/JCI30634
  5. Januzzi JL Jr. ST2 as a Cardiovascular Risk Biomarker: From the Bench to the Bedside. J Cardiovasc Transl Res. 2013;6(4):493-500. doi: 10.1007/s12265-013-9459-y
  6. Nadar SK, Shaikh MM. Biomarkers in Routine Heart Failure Clinical Care. Card Fail Rev. 2019;5(1):50-6. doi: 10.15420/cfr.2018.27.2
  7. Mueller T, Jaffe AS. Soluble ST2: Analytical considerations. Am J Cardiol. 2015;115(7 Suppl):8B-21B. doi: 10.1016/j.amjcard.2015.01.035
  8. Boisot S, Beede J, Isakson S, et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail. 2008;14(9):732-8. doi: 10.1016/j.cardfail.2008.06.415
  9. Mueller T, Dieplinger B, Gegenhuber A, et al. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem. 2008;54(4):752-6. doi: 10.1373/clinchem.2007.096560
  10. Копьева К.В., Гракова Е.В., Тепляков А.Т. Новые маркеры сердечной недостаточности: значение для диагностики и прогнозирования NT-proBNP и интерлейкиновых рецепторов - членов семейства ST2. Комплексные проблемы сердечно-сосудистых заболеваний. 2018;7(1):94-101
  11. Lupon J, de Antonio M, Vila J, et al. Development of a novel heart failure risk tool: The Barcelona Bio-Heart Failure Risk Calculator (BCN bio-HF Calculator). PLoS One. 2014;9(1):e85466. doi: 10.1371/journal.pone.0085466
  12. Emdin M, Aimo A, Vergaro G, et al. sST2 predicts outcome in chronic heart failure beyond NT-proBNP and high-sensitivity troponin T. J Am Coll Cardiol. 2018;72(19):2309-20. doi: 10.1016/j.jacc.2018.08.2165
  13. Gaggin HK, Motiwala S, Bhardwaj A, et al. Soluble concentrations of the interleukin receptor family member ST2 and 0-blocker therapy in chronic heart failure. Circ Heart Fail. 2013;6(6):1206-13. DOI:10.1161/ CIRCHEARTFAILURE.113.000457
  14. Dudek M, Kaluzna-Oleksy M, Migaj J, Straburzynska-Migaj E. Clinical value of soluble ST2 in cardiology. Adv Clin Exp Med. 2020;29(10):1205-10. doi: 10.17219/acem/126049
  15. Coronado MJ, Bruno KA, Blauwet LA, et al. Elevated sera sST2 is associated with heart failure in men №50 years old with myocarditis. J Am Heart Assoc. 2019;8(2):e008968. doi: 10.1161/JAHA.118.008968
  16. Farcaf AD, Anton FP, Goidescu CM, et al. Serum soluble ST2 and diastolic dysfunction in hypertensive patients. Dis Markers. 2017;2714095. doi: 10.1155/2017/2714095
  17. Chen C, Qu X, Gao Z, et al. Soluble ST2 in patients with nonvalvular atrial fibrillation and prediction of heart failure. Int Heart J. 2018;59(1):58-63. doi: 10.1536/ihj.16-520
  18. Okar S, Kaypakli O, §ahin DY, Ko<; M. Fibrosis marker soluble ST2 predicts atrial fibrillation recurrence after cryoballoon catheter ablation of nonvalvular paroxysmal atrial fibrillation. Korean Circ J. 2018;48(10):920-9. doi: 10.4070/kcj.2018.0047
  19. Ibrahim NE, Lyass A, Gaggin HK, et al. Predicting new-onset HF in patients undergoing coronary or peripheral angiography: Results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study. ESC Heart Fail. 2018;5(3):240-8. doi: 10.1002/ehf2.12268
  20. Patel DM, Thiessen-Philbrook H, Brown JR, et al. Association of plasma soluble ST2 and galectin 3 with cardiovascular events and mortality following cardiac surgery. Am HeartJ. 2020;220:253-63. doi: 10.1016/j.ahj.2019.11.014
  21. Lupon J, de Antonio M, Galan A, et al. Combined use of the novel biomarkers high sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment. Mayo Clin Proc. 2013;88(3):234-43. doi: 10.1016/j.mayocp.2012.09.016:234-43
  22. Anand IS, Rector TS, Kuskowski M, et al. Prognostic Value of Soluble ST2 in the Valsartan Heart Failure Trial. Circ Heart Fail. 2014;7(3):418-26. doi: 10.1161/CIRCHEARTFAILURE.113.001036
  23. Vorovich E, French B, Ky B, et al. Biomarker predictors of cardiac hospitalization in chronic heart failure: a recurrent event analysis. J Card Fail. 2014;20(8):569-76. doi: 10.1016/j.cardfail.2014.05.013
  24. Ahmad T, Fiuzat M, Neely B, et al. Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. JACC Heart Fail. 2014;2:260-8. doi: 10.1016/j.jchf.2013.12.004
  25. Yancy CW, Jessup M, Bozkurt B, et al. American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-239. doi: 10.1016/j.jacc.2013.05.019
  26. Gaggin HK, Szymonifka J, Bhardwaj A, et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronicheart failure. JACC Heart Fail. 2014;2(1):65-72. doi: 10.1016/j.jchf.2013.10.005
  27. Caselli C, D’Amico A, Ragusa R, et al. IL-33/ST2 pathway and classical cytokines in end-stage heart failure patients submitted to left ventricular assist device support: a paradoxic role for inflammatory mediators? MediatorsInflamm. 2013;2013:498703. doi: 10.1155/2013/498703
  28. Zilinski JL, Shah RV, Gaggin HK, et al. Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy. Crit Care. 2012;16(4):R135. doi: 10.1186/cc11440
  29. Dieplinger B, Mueller T. Soluble ST2 in heart failure. Clin Chim Acta. 2015;443:57-70. doi: 10.1016/j.cca.2014.09.021

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies